Skip to content
Esta página está disponible en españolCambiar →
GestorLensSign up

enGene Therapeutics (ENGNW): which funds own it

Health Care →(by SIC code, unreviewed)warrantData as of Jun 30, 2026 (Q2 2026) · updated on Nov 6, 2026

A 13F shows the portfolio at quarter-end and is filed up to 45 days later: these are not real-time positions and they may have changed.

Follow ENGNW for free
Share

Sections with a free account

1 concentrated manager holds it (+1 vs last quarter) with a median weight of 0.0%. 1 officer or director bought in 6 months.

Concentrated managers
1
All 13F: 10
Consensus
—
No score: it needs 5 or more concentrated managers
Price at Jun 30, 2026 (per 13F)
$0.29
reported value ÷ shares, not the quote · See current quote ↗

Quarter flow (concentrated managers)

Change in managers (0 → 1): 1 opened · 0 exited = +1

Net flow in the quarter: +$274K (+945 K shares) · bought $274K and sold $0Shares concentrated managers added minus those they cut, valued at the 13F quarter-end implied price, not each trade's price. It is a different measure from the change in managers: the two can have opposite signs.

Concentrated managers holding it

  • BVFNewly listed$274K0.0%+0.0 pp

Up to 15, sorted by position value. The percentage is the weight in each manager's portfolio.

Largest holders of ENGNW (all 13F filers)

The 10 13F filers with the most shares as of Jun 30, 2026, whatever their type (index firms usually come first). “Change”: shares added or cut versus the previous quarter, split-adjusted; “no data” = there is no comparable portfolio for the previous quarter (no filing, or a filing with its holdings under confidential treatment). “% of the company” only where shares outstanding are up to date. Entities of the same group file separately and some 13F filings include other managers: there may be double counting. With a free account: the top 25, the largest buyers and the largest sellers.

Fundamentals

12-month figures to Jul 31, 2026 · balance sheet as of Jul 31, 2026.

Profitability
Operating margin
—
Net margin
—
ROE
-56.6%
Growth
Revenue (TTM)
—
Revenue growth
—
Net income (TTM)
$-130M
Balance sheet
Net debt / EBITDA
—
Free cash flow (TTM)
$-104M
Quality vs sector
—

This company's sector comes from its SIC code, unreviewed, or has too few comparable companies: we do not compare it with its sector.

Figures from the statements the company filed with the SEC (10-K, 10-Q). Free cash flow = operating cash flow − capital expenditures; empty if the company does not report capex. “Quality vs sector”: 0 to 100, the average of its percentiles in ROE, operating margin, free-cash-flow margin, revenue and earnings growth and net debt / EBITDA (at least 3 needed) against companies in its sector above $300M. How each figure is calculated

Shares outstanding: buybacks and dilution

Diluted shares by fiscal year (split-adjusted)

2025: 51.1 M

51.1 M0
20232025

There is a jump that may be an undetected split: we do not show the changes.

Buybacks (FY 2025)
no data
Share issuance
no data
Stock-based compensation
$9.6M
Dividends paid
no data

From the statements the company filed with the SEC (10-K). The change compares average diluted shares of each fiscal year, on today's basis: negative = it bought back more than it issued; positive = dilution. “No data” = the company does not report that item under a tag we can read; it does not mean zero.

Earnings quality and debt

Operating cash flow ÷ net income (12 months)
no datanot calculated with negative net income
Interest coverage (operating income ÷ interest)
−41.1 timesnegative operating income
Debt due within 12 months
$199K0.00 times cash and investments

From the figures the company filed with the SEC. Cash flow over net income near or above 1 means earnings are collected in cash; far below, that part is accounting. Coverage says how many times operating income pays the latest fiscal year's interest. Maturities come from the debt note of the latest annual report, counted from its closing date. “No data” never means zero.

Insiders (Form 4)

Officers and directors who bought (6 m)
1
Amount (6 m)
$10.1K
CEO/CFO bought (12 m)
No

10% owners who bought (6 m): 0

Open-market purchases, excluding 10b5-1 plans. Officers and directors only; joint filers of the same purchase count as one. 10% owners with no role are shown separately. 0 = nobody bought; “no data” = we do not have its Form 4 filings.

Each of the company's Form 4 filings, on EDGAR ↗Latest trades, with date and filing →

Above 5% (13D/13G)

This list may be incomplete: we hold 13D and 13G filings made since December 2024. A holder above 5% that has not filed anything since then is not shown here.

No recent filings.

Flagged material events (8-K)

  • Jun 18, 2026Mediumfiling ↗

    Exit or restructuring costs (Item 2.05)

  • Jun 15, 2026Mediumfiling ↗

    Exit or restructuring costs (Item 2.05)

    «enGene Reports Second Quarter 2026 Financial Results and Provides Business Update»

  • Jul 16, 2026Routinefiling ↗

    Change in directors or officers (Item 5.02)

    «enGene Focuses Board to Support Planned Upcoming Regulatory and Commercial Milestones»

  • Jun 18, 2026Routinefiling ↗

    Change in directors or officers (Item 5.02)

  • Jun 15, 2026Routinefiling ↗

    Change in directors or officers (Item 5.02)

    «enGene Reports Second Quarter 2026 Financial Results and Provides Business Update»

  • May 7, 2026Routinefiling ↗

    Change in directors or officers (Item 5.02)

    «enGene Announces Updated Interim Results From LEGEND Pivotal Cohort»

  • Jan 21, 2026Routinefiling ↗

    Unregistered sale of equity securities (Item 3.02)

Alert items the company itself flagged in its 8-K filings with the SEC, most serious first. It is the form's label, with no interpretation from us: Item 5.02 covers routine appointments as well as a chief executive's departure; open the filing. The quoted headline is the original press release's.

All material events (8-K)

Earnings, agreements, financing, management changes and announcements from the last year, with a filter by type and a link to each filing.

Other Health Care stocks in managers' portfolios

Same sector and a similar number of concentrated managers holding them. It is a list to keep exploring, not a recommendation.

All of Health Care →

Follow ENGNW for free

If someone reports a 5%+ stake, we email you (if you turn it on). And when you come back, see whether concentrated managers got in or out. No credit card.

Follow ENGNW